<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898635</url>
  </required_header>
  <id_info>
    <org_study_id>2017-44</org_study_id>
    <nct_id>NCT03898635</nct_id>
  </id_info>
  <brief_title>Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis</brief_title>
  <official_title>Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis
      infection, causing mortality and disability in more than half of the patients. Current
      standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which
      does not take into account the differential ability of anti-tuberculosis drugs to penetrate
      the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy
      that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising
      antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of
      linezolid in the treatment of TBM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Medical Research Council grade deterioration</measure>
    <time_frame>From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time of Glasgow Coma Scale recovered to 15</measure>
    <time_frame>From the beginning of anti-tuberculosis treatment to the first documented recovery, assessed up to 5 years.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of body temperature returns to normal</measure>
    <time_frame>From the beginning of anti-tuberculosis treatment to the first documented recovery, assessed up to 5 years.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with new omplications</measure>
    <time_frame>From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years.</time_frame>
    <description>Hydrocephalus, cerebral infarction, epilepsy, brain abscess, tuberculoma</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Tuberculous Meningitis</condition>
  <arm_group>
    <arm_group_label>Background group</arm_group_label>
    <description>The treatment regimen does not include linezolid throughout the treatment course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Background-linezolid group</arm_group_label>
    <description>Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid initial group</arm_group_label>
    <description>Linezolid was in initial treatment regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.</description>
    <arm_group_label>Background-linezolid group</arm_group_label>
    <arm_group_label>Linezolid initial group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with central nervous system tuberculosis diagnosed and treated at Huashan
        Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients diagnosed as TBM from the electronic medical record system.

        Exclusion Criteria:

          -  Does not meet the established diagnostic criteria;

          -  Combine other pathogen central infections;

          -  Follow-up confirmed that the final diagnosis considers other diseases (such as tumors,
             autoimmune encephalitis, etc.);

          -  Our hospital has less than one week of anti-tuberculosis treatment;

          -  Lack of information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xian Zhou</last_name>
    <phone>(86)18801734036</phone>
    <email>zhouxian-13@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Feng Sun</last_name>
    <email>aaronsf1125@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious department of Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhong Zhang</last_name>
      <phone>(86)52889999</phone>
      <email>zhangwenhong@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Wen-hong Zhang</investigator_full_name>
    <investigator_title>Director of Division of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>linezolid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Meningeal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

